|
Synonyms: 1-7F9 | BMS-986015 | IPH2102
Compound class:
Antibody
Comment: Lirilumab (BMS-986015) is a fully human monoclonal antibody (mAb) which targets the KIRD2 subgroup of killer cell immunoglobulin like receptors (KIRs) on natural killer cells [1], being developed as an immuno-oncology clinical candidate. Identified targets include KIR2DL1, KIR2DL2, KIR2DL3, KIR2DS1 and KIR2DS2. Genes of KIR proteins are listed in HGNC family Killer cell immunoglobulin like receptors (KIR). ia an IgG4 isotype antibody considered suitable for a blocking , non-depleting mAb with clinical utility.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. |
| No information available. |
Summary of Clinical Use  |
| Lirilumab has reached Phase 2 clinical trial in acute myeloid leukemia (AML)- click here to link to ClinicalTrials.gov's list of Phase 2 lirilumab trials. Phase 1 trials in solid tumours and multiple myeloma (MM), assessing lirilumab in combination with other immuno-oncology agents are also underway. |
| Mechanism Of Action and Pharmacodynamic Effects |
| Lirilumab (BMS-986015) prevents inhibitory signaling by targeted KIRs and this elicits a stronger NK cell response to cancer cells [1]. |
